Answers are grounded in this paper and cite their sources.
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only cure for congenital amegakaryocytic thrombocytopenia (CAMT). However, transplant outcomes for patients progressing to myelodysplastic syndrome (MDS) with monosomy 7 remain largely unreported. Methods: We retrospectively analyzed five pediatric CAMT patients undergoing peripheral blood stem cell (PBSC) transplantation. All received uniform non-TBI myeloablative conditioning (busulfan, cyclophosphamide, rATG) with cyclosporine/methotrexate GVHD prophylaxis. Two had progressed to MDS with monosomy 7. Results: All five patients achieved rapid engraftment (median neutrophil 12 days, platelet 14 days) with donor chimerism > 99% at the last assessment and no primary graft failure. At a 3-year median follow-up, 80% (4/5) remain alive with sustained transfusion independence. The single mortality occurred in a patient with MDS with monosomy 7, who succumbed to grade IV hemorrhagic cystitis, in the setting of grade IV acute GVHD, at two months. Conclusion: In this small series, non-TBI myeloablative PBSC transplantation was associated with rapid engraftment and durable hematopoietic reconstitution in CAMT without MDS. In patients with pre-existing MDS/monosomy 7, outcomes were heterogeneous (one survivor, one death); given the small sample and concurrent risk factors, an independent effect of MDS/monosomy 7 cannot be established. These observations underscore the importance of early genetic diagnosis and timely HSCT referral.
No takes yet. Share an insight, caveat, or question.
Delkhah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: